Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction

NCT05184192 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

OTHER

Sponsor class

Conditions

COVID-19
Olfactory Disorder
Anosmia
Hyposmia
Parosmia

Interventions

DRUG: Gabapentin gelatin capsules 300mg
DRUG: Placebo

Sponsor

Washington University School of Medicine